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Abstract 
Background: Genetic damages and epigenetic factors are important in invasive breast cancer. PTEN 
gene is one of the most important tumor suppressor genes. Phosphatase and tensin homolog (PTEN) 
protein can be traced by immunohistochemistry methods. The purpose of this study was to determine 
the relationship of PTEN gene expression and pathological parameters in patients with breast cancer.  
Methods: This descriptive analytical research was conducted on 100 cases with breast cancer 
admitted to a hospital in Sabzevar, Iran, during 2010-13. Samples were fixed in formalin; tissue 
processing and taking sections was done. Then, the slides were stained by hematoxylin and eosin. 
Malignancy was diagnosed by two pathologists blindly. Expression of PTEN gene was evaluated after 
antigen retrieval with primary specific rabbit monoclonal PTEN antibody using by 
immunohistochemical method. Photos were taken by light microscope. Data were analyzed using chi-
square and Fisher’s exact tests. 
Findings: In 70 (70%) specimens, PTEN protein was detected. Protein stability was observed in total 
normal samples. No significant relationship was observed between the stage and grade of tumor, but 
there was significant relationship between PTEN gene expression and tumor grade and stage (P < 0.05). 
Over-expression of PTEN gene was lower in invasive ductal carcinoma compared to non-invasive breast 
cancers. 
Conclusion: Our study showed that PTEN gene expression is low in patients with high-grade breast 
tumors. Therefore, we may conclude that low expression of PTEN gene is accompanied with bad 
prognosis in patients with breast cancer. 
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